- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
ProMIS Neurosciences Inc (PMN)
ProMIS Neurosciences Inc stock price live, this page displays NASDAQ PMN stock exchange data. View the PMN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the ProMIS Neurosciences Inc real time stock price chart below.
What Is the ProMIS Neurosciences Inc Stock Price Today?
The ProMIS Neurosciences Inc stock price today is 14.660.
What Is the Stock Symbol for ProMIS Neurosciences Inc?
The stock symbol for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMN quote. (ISIN: CA74346M5054)
What Is the ProMIS Neurosciences Inc Stock Price Today?
The ProMIS Neurosciences Inc stock price today is 14.660.
What Is the Stock Symbol for ProMIS Neurosciences Inc?
The stock symbol for ProMIS Neurosciences Inc is "PMN."
What Stock Exchange Does ProMIS Neurosciences Inc Trade On?
ProMIS Neurosciences Inc is listed and trades on the NASDAQ stock exchange.
Is ProMIS Neurosciences Inc a Good Stock to Buy?
Determining whether ProMIS Neurosciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PMN quote. (ISIN: CA74346M5054)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.270
14.960
52 wk Range
6.270
27.400
PMN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
14.27014.960
52 wk Range
6.27027.400
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PMN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
43.979
Upside
+199.99%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 43.979
(+199.99% Upside)
ProMIS Neurosciences Inc Earnings Call Summary for Q2/2026
- ProMIS ended Q2 with CAD 53.4M cash vs CAD 6.1M at year-end 2025, sufficient to fund operations through 2027 and Q1 2027 data readout.
- Q2 net loss widened to CAD 11.7M (CAD 1.28/share) from CAD 10.1M (CAD 7.26/share) year-over-year, driven by increased clinical activity.
- Alzheimer's drug PMN310 showed positive interim safety data with zero ARIA-E cases; PRECISE-AD trial enrolled 144 patients across 21 U.S. sites.
- Management preparing for potential single registration study if Q1 2027 data remain positive; holds FDA Fast Track designation for PMN310.
- Pipeline expansion includes PMN267 for ALS and PMN442 for synucleinopathies, both expected to enter clinic within 6-9 months.
Last Updated: 2026/08/13, 23:50
Read Full TranscriptEarnings
Latest Release
Aug 13, 2026
EPS / Forecast
-1,28 / -0,18
Revenue / Forecast
-- / --
Compare PMN to Peers and Sector
Metrics to compare | PMN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPMNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.1x | −1.7x | −0.4x | |
PEG Ratio | 0.09 | −0.20 | 0.00 | |
Price/Book | 2.7x | 1.4x | 2.6x | |
Price / LTM Sales | - | 2.2x | 3.1x | |
Upside (Analyst Target) | 135.5% | 831.1% | 47.9% | |
Fair Value Upside | Unlock | 8.6% | 6.3% | Unlock |
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington’s disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the ProMIS Neurosciences (PMN) Stock Price Today?
The ProMIS Neurosciences stock price today is 14,660 USD.
What Stock Exchange Does ProMIS Neurosciences Trade On?
ProMIS Neurosciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for ProMIS Neurosciences?
The stock symbol for ProMIS Neurosciences is "PMN."
What Is the ProMIS Neurosciences Market Cap?
As of today, ProMIS Neurosciences market cap is 133,260M USD.
What Is ProMIS Neurosciences's Earnings Per Share (TTM)?
The ProMIS Neurosciences EPS (TTM) is -8,456.
When Is the Next ProMIS Neurosciences Earnings Date?
ProMIS Neurosciences will release its next earnings report on May 12, 2026.
From a Technical Analysis Perspective, Is PMN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has ProMIS Neurosciences Stock Split?
ProMIS Neurosciences has split 2 times.
How Many Employees Does ProMIS Neurosciences Have?
ProMIS Neurosciences has 11 employees.
What is the current trading status of ProMIS Neurosciences (PMN)?
As of Aug 17, 2026, ProMIS Neurosciences (PMN) is trading at a price of 14,660 USD, with a previous close of 14,860 USD. The stock has fluctuated within a day range of 14,270 USD to 14,960 USD, while its 52-week range spans from 6,270 USD to 27,400 USD.
What Is ProMIS Neurosciences (PMN) Price Target According to Analysts?
The average 12-month price target for ProMIS Neurosciences is 43,979 USD, with a high estimate of 100.55323139 USD and a low estimate of 18.24870167 USD. 8 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +199,99% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.